🔬 智慧醫療的經濟評估與給付 Economic evaluation of AI-enabled health technologies
AI 醫療經濟（AI health economics）是本團隊的主要研究方向。以 AI 心電圖（AI-ECG）篩檢與預警系統為核心案例，評估智慧醫療器材（SaMD）的成本效益與健保給付策略，成果發表於 npj Digital Medicine、Journal of Medical Systems、Canadian Journal of Cardiology 等期刊。
Economic evaluation of AI-enabled medical technologies — with a focus on AI-ECG screening and alert systems — and reimbursement frameworks for Software as a Medical Device (SaMD).
💊 藥物經濟評估 Pharmacoeconomics
針對偏頭痛預防藥物、腎性貧血治療、癌症標靶與細胞治療（BiTE、CAR-T）等主題進行成本效益與成本效用分析，支持臨床用藥與健保給付決策。
Cost-effectiveness and cost-utility analyses of pharmaceuticals, including migraine prevention, renal anemia, and oncology therapies (bispecific T-cell engagers and CAR-T).
📊 疾病負擔與真實世界證據 Disease burden and real-world evidence
運用健保資料庫、醫院臨床資料與國際合作調查，分析類風濕性關節炎、肌肉骨骼疾病、離島醫療後送等議題的疾病與經濟負擔。
Cost-of-illness and burden-of-disease studies using NHI claims, hospital data, and international surveys (e.g., rheumatoid arthritis, musculoskeletal disorders, medical evacuation in remote islands).
🧰 研究方法 Methods
決策分析模型（decision tree、Markov model）、機率敏感度分析、系統性文獻回顧與網路統合分析（NMA）、試驗為基礎的經濟評估與真實世界資料分析。
Decision-analytic modelling (decision trees and Markov models), probabilistic sensitivity analysis, systematic review and network meta-analysis, trial-based economic evaluation, and real-world data analysis.
🤝 歡迎合作 Collaboration
團隊與英國格拉斯哥大學 HEHTA、DIGI-HTA Asia Working Group 及國內醫學中心密切合作。歡迎跨國經濟評估與 HTA 研究、智慧醫療產品價值評估與市場准入、產學合作與委託研究，請來信 pinghsuan.h@mail.ndmutsgh.edu.tw。
We collaborate closely with HEHTA (University of Glasgow), the DIGI-HTA Asia Working Group, and medical centers in Taiwan. We welcome international joint studies, value assessment and market access projects for digital health, and industry collaboration: pinghsuan.h@mail.ndmutsgh.edu.tw